VYNE Therapeutics (VYNE) Income towards Parent Company (2017 - 2025)
VYNE Therapeutics (VYNE) posted Income towards Parent Company of -$8000.0 for Q2 2025, little changed on a QoQ basis from -$8000.0 in Q1 2025, and up 27.27% year-over-year from -$6285.7 in Q2 2024.
VYNE Therapeutics (VYNE) Income towards Parent Company (2017 - 2025) Analysis & Trends
VYNE Therapeutics' Income towards Parent Company history runs 9 years deep, the most recent figure standing at -$8000.0 for Q2 2025.
- Quarterly Income towards Parent Company rose 27.27% year-over-year to -$8000.0 in Q2 2025, while the trailing twelve-month figure through Mar 2026 was -$16000.0 (up 40.74% YoY) and the FY2025 annual result came in at $253000.0, up 1037.04% from the prior year.
- Income towards Parent Company was -$8000.0 for Q2 2025 at VYNE Therapeutics, roughly flat from -$8000.0 in the prior quarter.
- Across five years, Income towards Parent Company topped out at $13.4 million in Q1 2022 and bottomed at -$9.7 million in Q1 2021.
- A 5-year average of -$1.1 million and a median of -$36000.0 in 2023 frame the typical range for Income towards Parent Company.
- Annual changes were most pronounced in 2022 — Income towards Parent Company surged 238.14% — and 2023, when it plunged 151.47%.
- VYNE Therapeutics' Income towards Parent Company stood at -$3.2 million in 2021, then surged by 31.71% to -$2.2 million in 2022, then surged by 98.35% to -$36000.0 in 2023, then soared by 77.78% to -$8000.0 in 2024, then changed by 0.0% to -$8000.0 in 2025.
- Business Quant data shows VYNE's Income towards Parent Company at -$8000.0 in Q2 2025, -$8000.0 in Q1 2025, and -$8000.0 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - |
| 10 | VYNE Therapeutics | 1.19 Bn | 1.16 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | -8,000.00 |
| Mar 31, 2025 | -8,000.00 |
| Dec 31, 2024 | -8,000.00 |
| Jun 30, 2024 | -11,000.00 |
| Mar 31, 2024 | -8,000.00 |
| Dec 31, 2023 | -36,000.00 |
| Sep 30, 2023 | -513,000.00 |
| Jun 30, 2023 | -20,000.00 |
| Mar 31, 2023 | -10,000.00 |
| Dec 31, 2022 | -2.18 Mn |
| Sep 30, 2022 | -204,000.00 |
| Jun 30, 2022 | -241,000.00 |
| Mar 31, 2022 | 13.36 Mn |
| Dec 31, 2021 | -3.20 Mn |
| Sep 30, 2021 | -7.01 Mn |
| Jun 30, 2021 | -9.24 Mn |
| Mar 31, 2021 | -9.67 Mn |
| Dec 31, 2020 | -23.18 Mn |
| Sep 30, 2020 | -24.71 Mn |
| Jun 30, 2020 | -167.44 Mn |